CLINICAL_TRIALS
trial_result
· 2025-10-01
Clinical Trial Update: A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH [Phase 2]
Summary
Phase 2b study of tildacerfont in adults with congenital adrenal hyperplasia was terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Spruce Biosciences | Conditions: Congenital Adrenal Hyperplasia | Phase 2 | Status: TERMINATED | Results posted: 2025-10-01